Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 70954-975

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 70954-975). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Fig 1)

A chart depicting the geometric mean ratio and 90% confidence interval for the pharmacokinetic interaction of coadministered drugs with Sacubitril and Valsartan. The x-axis shows change relative to reference, and data points represent AUC and Cmax for various drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*

FDA Label Image

Figure-2 (Fig 2)

A forest plot comparing the pharmacokinetic parameters AUC and Cmax for LBQ657 and Valsartan. The chart shows geometric mean ratios with 90% confidence intervals across various population subgroups, including renal and hepatic impairment levels, age, sex, and race. Each subgroup's data is presented as change relative to reference values.*

FDA Label Image

Fig-3 (Fig 3)

Three Kaplan-Meier survival curves from the PARADIGM-HF study comparing Sacubitril and Valsartan versus Enalapril. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations, Figure B shows time to occurrence of cardiovascular death, and Figure C shows time to first occurrence of heart failure hospitalizations. Each chart plots cumulative failure rate (%) over time in days, including risk tables below.*

FDA Label Image

Fig-4 (Fig 4)

A forest plot comparing the hazard ratios of Sacubitril and Valsartan versus Enalapril across various patient subgroups. The chart displays percentage of total population, number of events, and hazard ratios with 95% confidence intervals for categories including age, sex, weight, race, region, NYHA class, estimated GFR, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, heart failure history, and ICD presence.*

FDA Label Image

Fig-5 (Fig 5)

A line graph titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF' comparing mean number of events per 100 patients over time (days) since randomization. Two lines represent Sacubitril and Valsartan, showing a lower and higher mean number of events respectively, with patient numbers at risk listed below the x-axis at various time points.*

FDA Label Image

Fig-6 (Fig 6)

A forest plot chart comparing the rate ratios for various subgroups treated with Sacubitril and Valsartan versus Valsartan alone. The chart lists subgroups such as age, gender, race, region, diabetic status, left ventricular ejection fraction (LVEF), atrial fibrillation history, NT-proBNP levels, systolic blood pressure, and other baseline characteristics. Each subgroup features a point estimate with 95% confidence intervals indicating relative effectiveness or outcomes between the two treatments.*

FDA Label Image

Fig-7 (Fig 7)

A dual line chart showing hazard ratios with 95% confidence intervals for Sacubitril and Valsartan compared to enalapril and valsartan. The x-axis represents left ventricular ejection fraction at screening (%) from 15 to 75, while the y-axis represents the hazard ratio, ranging approximately from 0.5 to 1.4. The left graph compares Sacubitril and Valsartan vs. enalapril, and the right graph compares Sacubitril and Valsartan vs. valsartan.*

FDA Label Image

Label-1 (Label 1)

Label for Sacubitril and Valsartan Tablets 24 mg/26 mg, film-coated tablets, with a quantity of 60 tablets. The label includes storage instructions, distributor information for ANI Pharmaceuticals, Inc., a barcode, and issuance date of 05/2025. The product is prescription only.*

FDA Label Image

Label-2 (Label 2)

Label for Sacubitril and Valsartan Tablets, 24 mg/26 mg strength. The label indicates 180 film-coated tablets, distributed by ANI Pharmaceuticals, Inc. It includes storage instructions, dosage guidance reference, and a barcode. The label design features the brand name prominently and dosage strength in white text on a black background.*

FDA Label Image

Label-3 (Label 3)

Label for Sacubitril and Valsartan Tablets 49 mg/51 mg by ANI Pharmaceuticals, Inc. The label includes dosage form as film-coated tablets, package count of 60 tablets, and storage instructions. The label features the product NDC 70954-976-20 and states it is Rx only.*

FDA Label Image

Label-4 (Label 4)

Label for Sacubitril and Valsartan Tablets 49 mg/51 mg, film-coated oral tablets. The label includes product strength, NDC 70954-976-30, quantity of 180 tablets, and distributor information for ANI Pharmaceuticals, Inc., Baudette, MN. Storage instructions and a barcode are also shown.*

FDA Label Image

Label-5 (Label 5)

Label for Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablets, distributed by ANI Pharmaceuticals, Inc. The label indicates an NDC of 70954-977-20 and a quantity of 60 tablets. Storage instructions, dosage directions, and a barcode are also visible on the label.*

FDA Label Image

Label-6 (Label 6)

Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablet label. The label shows a quantity of 180 tablets, distributed by ANI Pharmaceuticals, Inc. It includes storage instructions, dosage reference to prescribing information, and a barcode. The label also states that the product is prescription only.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of sacubitril and valsartan showing molecular components and arrangement, including sodium ions (Na+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.